TRIB3 and hepatocellular carcinoma: Remarkably, both overexpression and knockout of TRIB3 in an in vitro culture system failed to significantly impact the proliferation or survival of hepatoma cells in the presence or absence of sorafenib, despite sorafenib's inherent ability to inhibit cell proliferation, aligning with established knowledge (Figure3A,B).